We’re going to see areas, of course, that enhance the portfolio or help us to continue to give us capabilities or products that we don’t have today. I think in some ways, that’s how you can think about Mirati. Mirati continues to diversify our oncology business away [indiscernible] towards targeted therapies. We’re very excited about that opportunity, but I think generally speaking the way we approach business development will be largely consistent again, that we’ll be focusing on great science that can enhance the growth profile of the company.
Tim Power: Great, thanks. Keith, can we go to our last question, please?
Operator: Yes, and that comes from Dane Leone with Raymond James.
Sean: Hi guys, this is Sean [ph] on for Dan. Thanks for taking the questions. Maybe we can get a little bit more color on those Camzyos script trends. It does appear that the number of patients entering the hub may be slightly slowing, so just any further color on what you’ve been hearing from physicians on how burdensome the REMS program is and what you expect for further growth. Thanks.
Adam Lenkowsky: Sure Sean, I’ll take that question. We’re very pleased with what we’re seeing in the launch of Camzyos. We continue to see week-over-week consistency in patient starts and rapid conversion of patients from the hub to commercial. As we’ve all said, we would expect to see steady, consistent and sustained uptake for this product into the distant future. We don’t expect an inflection but rather an accumulation of patients coming onto treatment and staying on treatment for a very long period of time. Right now, we’ve got 5,000 patients in the hub and approximately 3,500 patients on commercial product, so that coupled with patient and physician feedback, which continues to be very strong, we’re focusing on driving penetration at our top centers where we have 90% adoption in our top 100 centers, and expanding use outside of those COEs. We’re also focused on increasing diagnosis rates by activating patients, and as you know, we recently received approval internationally as well in Europe, so that will also be a contributor to growth.
Taken together, we’re very confident this will lead to continued and sustained growth of this important product.
Chris Boerner: Maybe I’ll close, so first, thank you all for joining the call. I know it’s a very busy day. What I would just say to summarize where we are is, look, this team continues to be fixated on driving the growth profile of the company. How we go about doing that is, as we’ve discussed on the call, we’re going to continue to drive in-line product performance. The new product portfolio, we have continued very strong conviction in the long-term potential of this portfolio. Our focus is going to be continuing to drive where we have momentum today and accelerate those products where we need to accelerate, and that focus on execution transcends across the entire portfolio, including continuing to drive execution in R&D and continuing to find and source really attractive assets externally.
With that, we’ll close the call, and as always, the team is available to answer any questions following today’s discussion. Hope you all have a good day and rest of the week.
Operator: Thank you. The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
